【佳學(xué)基因檢測(cè)】通過(guò)基因檢測(cè)及人工智能大數(shù)據(jù)分析乳腺癌和其他癌癥中 APOBEC3B 表達(dá)與不良預(yù)后和臨床后果的關(guān)系

腫瘤基因檢測(cè)哪家醫(yī)院賊好解析

閱讀腫瘤的正確化治療及靶向藥物選擇發(fā)現(xiàn)《Tumour Biol》在.?2022;44(1):153-169.發(fā)表了一篇題目為《通過(guò)基因檢測(cè)及人工智能大數(shù)據(jù)分析乳腺癌和其他癌癥中 APOBEC3B 表達(dá)與不良預(yù)后和臨床后果的關(guān)系》腫瘤靶向藥物治療基因檢測(cè)臨床研究文章。該研究由Sima Jafarpour,?Maryam Yazdi,?Reza Nedaeinia,?Sepideh Ghobakhloo,?Rasoul Salehi等完成。促進(jìn)了腫瘤的正確治療與個(gè)性化用藥的發(fā)展，進(jìn)一步強(qiáng)調(diào)了基因信息檢測(cè)與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究?jī)?nèi)容關(guān)鍵詞：

乳腺癌,載脂蛋白,人工智能,大數(shù)據(jù),治療效果

腫瘤靶向治療基因檢測(cè)臨床應(yīng)用結(jié)果

基因檢測(cè)結(jié)果如何知道乳腺癌的治療效果導(dǎo)讀：關(guān)于載脂蛋白 B mRNA 編輯酶催化亞基 3B APOBEC3B、(A3B) 過(guò)表達(dá)與癌癥預(yù)后不良、轉(zhuǎn)移和化療耐藥性的關(guān)聯(lián)性是乳腺癌基因解碼的一個(gè)關(guān)注焦點(diǎn)。通過(guò)乳腺癌治療方法與效果的基因影響，乳腺癌正確治療團(tuán)隊(duì)進(jìn)行了系統(tǒng)回顧和薈萃分析，以確定其在乳腺癌和其他一些惡性腫瘤中的預(yù)后價(jià)值和臨床病理學(xué)特征。乳腺癌的治療方式與治療效果的研究材料和方法：PubMed、Scopus、Cochrane Library、Web of Science 和 EMBASE 檢索到 2022 年 2 月A3B 與乳腺癌、卵巢癌、胃腸道癌和肺癌的關(guān)系。評(píng)估了具有 95% 置信區(qū)間 (CI) 的匯總風(fēng)險(xiǎn)比，以評(píng)估所研究癌癥的無(wú)病生存期、總生存期 (OS) 和無(wú)反復(fù)生存期 (RFS)?；驒z測(cè)結(jié)果如何知道乳腺癌的治療效果的研究結(jié)果：納入了 3700 多名患者在這個(gè)大數(shù)據(jù)調(diào)查中。 A3B 水平升高與 總生存期 低（合并 HR = 1.30；95% CI：1.09-1.55，P < 0.01）、無(wú)病生存期 差（合并 HR = 1.66；95% CI：1.17-2.35，P < 0.01）和無(wú)反復(fù)生存期 差（HR = 1.51, 95% CI:1.11-2.04, P = 0.01）。亞組分析顯示，高 A3B 表達(dá)基因檢測(cè)與肺（HR = 1.85，95% CI：1.40-2.45）和乳腺癌（HR = 1.38，95% CI：1.00-1.89）的較差 總生存期 相關(guān)。 A3B的高表達(dá)與臨床病理特征沒(méi)有顯著相關(guān)性?；驒z測(cè)結(jié)果如何知道乳腺癌的治療效果的研究結(jié)論：APOBEC3B過(guò)表達(dá)基因檢測(cè)僅在某些癌癥類型中與較差的總生存期、無(wú)病生存期和無(wú)反復(fù)生存期有關(guān)，不能預(yù)測(cè)所有癌癥的普遍作用。

腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國(guó)際數(shù)據(jù)庫(kù)描述：

Introduction:?Controversy exists regarding the association of apolipoprotein B mRNA editing enzyme catalytic subunit 3B APOBEC3B, (A3B) overexpression and poor prognosis, metastasis, and chemotherapy drug resistance in cancers. Here we conducted a systematic review and meta-analysis to determine its prognostic value and clinicopathological features in breast cancer and some other malignancies.Materials and methods:?PubMed, Scopus, Cochrane Library, Web of Science, and EMBASE were searched up to Feb 2022 for the association of A3B with breast, ovarian, gastrointestinal and lung cancers. The pooled hazard ratios with 95% confidence interval (CI) were evaluated to assess disease-free survival (DFS), overall survival (OS), and recurrence-free survival (RFS) in cancers under study.Results:?Over 3700 patients were included in this meta-survey. Elevated levels of A3B were significantly related to low OS (pooled HR = 1.30; 95% CI:1.09-1.55, P < 0.01), poor DFS (pooled HR = 1.66; 95% CI:1.17-2.35, P < 0.01) and poor RFS (HR = 1.51, 95% CI:1.11-2.04, P = 0.01). Subgroup analysis revealed that high A3B expression was associated with poor OS in lung (HR = 1.85, 95% CI: 1.40-2.45), and breast cancers (HR = 1.38, 95% CI: 1.00-1.89). High expression of A3B did not display any significant association with clinicopathologic features.Conclusion:?APOBEC3B overexpression is related to poor OS, DFS and RFS only in some cancer types and no generalized role could be predicted for all cancers.